How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

13,562 results for

Ages and Stages Questionnaire

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. The measurement properties of sleep questionnaires for adults with pain conditions: a systematic review

The measurement properties of sleep questionnaires for adults with pain conditions: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia, duration of ischemia and duration

2019 PROSPERO

42. Systematic review and meta-analysis to assess the psychometric properties of health-related quality of life questionnaires (HRQoL) in bronchiectasis

Systematic review and meta-analysis to assess the psychometric properties of health-related quality of life questionnaires (HRQoL) in bronchiectasis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content (...) ruler software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac

2019 PROSPERO

43. Identification and comparison of existing prediction models and questionnaires to determine vitamin D status in adults - a systematic review

Identification and comparison of existing prediction models and questionnaires to determine vitamin D status in adults - a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration (...) software. In case data are not reported or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia

2019 PROSPERO

44. A reliability generalization meta-analysis for the patient-rated tennis elbow evaluation questionnaire (PRTEE)

A reliability generalization meta-analysis for the patient-rated tennis elbow evaluation questionnaire (PRTEE) Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files (...) or unclear, we will attempt to contact authors by e-mail (max. 2 attempts). In case an outcome is measured at multiple time points, data from the time point where efficacy is highest will be included. ">Methods for data extraction Example: Experimental groups, control group(s) and number of animals per group. ">Data to be extracted: study design Example: Species, sex, weight, age, co‐morbidity, anaesthetic agent used, method of induction of cardiac ischemia, duration of ischemia and duration

2019 PROSPERO

45. ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease

ESMO–ESGO Consensus Conference Recommendations on Ovarian Cancer: Pathology and Molecular Biology, Early and Advanced Stages, Borderline Tumours and Recurrent Disease SPECIAL ARTICLE ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease † N. Colombo 1 * , C. Sessa 2 , A. du Bois 3 , J. Ledermann 4 , W. G. McCluggage 5 , I. McNeish 6 , P. Morice 7 , S. Pignata 8 , I. Ray-Coquard 9 , I (...) jointlydevelopedclinicallyrelevant andevidence-based recommendationsinseveralselectedareas inorderto improvethequalityofcare forwomenwithovariancancer. TheESMO– ESGO consensusconferenceonovariancancerwasheldon 12–14April2018inMilan,Italy,andcomprisedamultidisciplinary panelof 40leadingexpertsin themanagementofovariancancer. Beforetheconference,the expertpanel workedonfive clinically relevantquestions regardingovariancancerrelating toeachofthefollowingfour areas:pathologyandmolecular biology,early-stage andborderlinetumours

2019 European Society for Medical Oncology

46. Validity of the ages and stages questionnaires in term and preterm infants. (PubMed)

Validity of the ages and stages questionnaires in term and preterm infants. This study assessed the concurrent validity of the parent-completed developmental screening measure Ages and Stages Questionnaires, Third Edition (ASQ-3) compared with the Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) in children born term, late preterm, or extremely preterm at 8, 18, or 30 months of corrected gestational ages (CGA).Data were collected from 306 term and preterm children (...) ages 8, 18, and 30 months' CGA recruited from an ambulatory well-child clinic in Santiago, Chile. Parents completed the ASQ-3 in their homes, and afterward a trained professional administered the Bayley-III in a clinic setting. On the ASQ-3, the presence of any domain screened <2 SDs below the mean area score was considered a positive screen (indicating failure or delay). A Bayley-III score less than ≤1 SD indicated mild or severe delay.ASQ-3 showed adequate psychometric properties (75% sensitivity

Full Text available with Trip Pro

2013 Pediatrics

47. The Diabetes Intention, Attitude, and Behavior Questionnaire: evaluation of a brief questionnaire to measure physical activity, dietary control, maintenance of a healthy weight, and psychological antecedents (PubMed)

questions based on the Theory of Planned Behavior. Items were developed using published literature, input from health care professionals, and qualitative research findings in patients with and without type 2 diabetes mellitus (T2DM). In Stage I of the study, 23 adults with T2DM were interviewed to evaluate the content and clarity of the DIAB-Q. In Stage II 1,015 individuals with T2DM completed the DIAB-Q and supplemental questionnaires, including the Short Form-36 acute (SF-36), section III (...) of the Multidimensional Diabetes Questionnaire, the Summary of Diabetes Self-Care Activities questionnaire, and self-administered items relevant to the treatment and management of T2DM (eg, blood pressure and glycated hemoglobin [HbA1c]) at baseline and 3-7 days later. Once the DIAB-Q scale structure was determined, its test-retest reliability, construct validity, and known-groups validity were evaluated, and minimal clinically important change was estimated.In Stage I, the 23 respondents surveyed generally reported

Full Text available with Trip Pro

2016 Patient preference and adherence

48. Assessment of Body Image, Sexual Function, and Attractiveness in Women With Genital Prolapse: A Cross-Sectional Study With Validation of the Body Image in the Pelvic Organ Prolapse (BIPOP) Questionnaire. (PubMed)

Scale questionnaire (BAQ) (scored from 5 to 35, with higher score indicating better body image). We also included 100 control women who completed the BAQ Attractiveness subscale questionnaire.The main outcome measure included BIPOP, FSFI, and BAQ Attractiveness scores.Mean BIPOP scores were 3.09 ± 1.08 in women with any POP, 3.05 ± 1.00 in those with lesser-stage POP (1 or 2), and 3.13 ± 1.15 in those with advanced-stage POP (3 or 4). There were no significant differences in score according (...) to prolapse staging (P = .71). FSFI scores were independently associated with BIPOP scores (β = -0.052; P = .02). The mean scores for the BAQ Attractiveness subscale was 17.01 ± 4.07 in women with POP and 16.97 ± 4.60 in those without POP (P = .93). Older age was the sole characteristic associated with being sexually inactive in women with POP; regarding sexual function, a better body image and higher attractiveness scores were independently associated with a higher FSFI score. As for the Portuguese

2019 Journal Of Sexual Medicine

49. Psychometric evaluation of an interview-administered version of the WHOQOL-BREF questionnaire for use in a cross-sectional study of a rural district in Bangladesh: an application of Rasch analysis. (PubMed)

Psychometric evaluation of an interview-administered version of the WHOQOL-BREF questionnaire for use in a cross-sectional study of a rural district in Bangladesh: an application of Rasch analysis. This study aimed to validate the psychometric properties of the World Health Organization Quality of Life Instrument, Short Form (WHOQOL-BREF) questionnaire for use in a rural district of Bangladesh.This cross-sectional study recruited a multi-stage cluster random sample of 2425 participants from (...) ] = 36.47, p = 0.013, Person Separation Index (PSI) = 0.773), four-items for the psychological ([Formula: see text] = 28.30, p = 0.029, PSI = 0.708) and five-items for the environmental ([Formula: see text] = 36.97, p = 0.011, PSI = 0.804) domain was applied, which showed adequate internal consistency, reliability, unidimensionality, and similar functioning for different age-sex distributions.The modified WHOQOL-BREF questionnaire translated into Bengali language appeared to be a valid tool

Full Text available with Trip Pro

2019 BMC health services research

50. The vascular access questionnaire: a single centre UK experience. (PubMed)

The vascular access questionnaire: a single centre UK experience. Haemodialysis is capable of prolonging life in patients with end stage renal disease, however this therapy comes with significant negative impact on quality of life. For patients requiring haemodialysis, the need for an adequately functioning vascular access (VA) is an everyday concern. The Vascular Access Questionnaire (VAQ) provides a mechanism for identifying and scoring factors in haemodialysis that impact on patients (...) ' quality of life and perception of their therapy.Between April 2017-18 the VAQ was administered to prevalent haemodialysis patients at 10 units in the West Midlands via structured interviews.749 of 920 potentially eligible patients completed the survey. The mean VAQ score was seen to improve significantly with age (7.7 in < 55 vs. 3.8 in 75+) and the duration of access (8.9 if less than 1 month old vs. 5.0 at a year). Better average scores were demonstrated for Arteriovenous fistulas (AVF) than other

2019 BMC Nephrology

51. Psychometric assessment of the Chinese version of the Problems and Needs in Palliative Care questionnaire-short version in advanced cancer patients. (PubMed)

), spiritual and psychological problems and needs between male and female patients; ADL, physical, social and financial problems and needs between age groups; and autonomic problems and needs between patients with different cancer stages. Statistically significant correlations (p < 0.05) were detected between the PNPC-sv and the EORTC QLQ-C30 in the majority of the sub-scores (positive correlations) and total scores (negative correlations). The Cronbach's alpha of the total scale was 0.88 and 0.91 (...) Psychometric assessment of the Chinese version of the Problems and Needs in Palliative Care questionnaire-short version in advanced cancer patients. To determine the validity, reliability and acceptability of the Mandarin Chinese version of the Problems and Needs in Palliative Care questionnaire-short version (PNPC-sv) for measuring problems and palliative care needs among patients with advanced cancer.This was a validation study using a forward- and backward- translation procedure, a panel

2019 BMC Palliative Care

52. Screening for impaired vision in community-dwelling adults aged 65 years and older in primary care settings

to deter- mine the quality of evidence and strength of recommendation (Box 1). The evidence-to-decision framework is provided in Appendix 2 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/ cmaj.171430/-/DC1). The Knowledge Translation team at St. Michael’s Hospital (Toronto, Ontario) engaged members of the public on behalf of the task force at two stages of guideline development. In the first phase, 15 participants aged 58 to 78 years rated outcomes to inform the systematic review, by means (...) Screening for impaired vision in community-dwelling adults aged 65 years and older in primary care settings E588 CMAJ | MAY 14, 2018 | VOLUME 190 | ISSUE 19 © 2018 Joule Inc. or its licensors I mpaired vision is an important health burden in both devel- oped and developing countries, particularly among older adults. 1 The 2006 Participation and Activity Limitation Survey found that 13% of Canadians aged 75 years and older had a “see- ing limitation,” with 31% described as severe, compared

2018 CPG Infobase

53. Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome

and week 103 of the clinical study; discontinuation rates for melatonin immediate-release were extrapolated separately based on a single estimate at 12 weeks of follow-up. Alternative approaches were provided on request as additional analyses. EQ-5D or alternative questionnaires were not included in the key clinical studies described above. Due to the paucity of utility data relevant to this indication, no estimates of baseline utility were available. The company conducted a multi-stage mapping (...) Melatonin (Slenyto) - Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome 1 Published 9 September 2019 1 SMC2168 melatonin 1mg and 5mg prolonged-release tablets (Slenyto®) Flynn Pharma Ltd 9 August 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised

2019 Scottish Medicines Consortium

54. Evaluation of Eat Well Keep Active (Stage 2)

Evaluation of Eat Well Keep Active (Stage 2) December 2016 Evaluation of Eat Well Keep Active (Stage 2)Eat Well Keep Active Report Stage 2 2016 Roma Robertson and Dr Ruth Jepson, SCPHRP This report describes the findings of a prospective evaluation involving participants in two CHANGES Eat Well – Keep Active courses (starting in November 2013 and June 2014). Acknowledgements We would like to thank all the Eat Well – Keep Active Course attendees who completed our questionnaires. We would also (...) of effects seen in Stage 1 • determine whether these effects were maintained over the longer term • determine which effects are maintained over the longer term and which are not. 6Eat Well Keep Active Report Stage 2 2016 MethodsEat Well Keep Active Report Stage 2 2016 This stage of the evaluation used quantitative (longitudinal postal questionnaires) methods. The Stage 1 questionnaire was amended and piloted on an Eat Well - Keep Active course which started on June 6th 2013. The responses raised concerns

2016 Scottish Collaboration for Public Health Research & Policy

55. Diagnosis, staging and treatment of patients with Lung Cancer

not demonstrated an improvement in overall survival and is not recommended. (B) 2.6.5.3 In patients with stage IV NSCLC who do not experience disease progression after 4-6 cycles of platinum-based double agent chemotherapy, there is insufficient evidence to recommend maintenance therapy with erlotinib. (B) 2.6.6.1 In elderly patients (age 70-79 years) with stage IV NSCLC who have good performance status and limited co-morbidities, treatment with a platinum doublet chemotherapy is recommended. (B) 2.6.6.2 (...) In patients with stage IV NSCLC with a performance status of 2, single agent chemotherapy may be considered. Platinum doublet chemotherapy is suggested over single agent chemotherapy if the performance status of 2 is cancer related rather than co-morbidity associated. (B) 2.6.6.3 Unfit patients of any age (performance status (3-4)) do not benefit from cytotoxic chemotherapy. However if patients harbor an EGFR or ALK mutation positive tumour, they may be considered for treatment with targeted therapies. (C

2017 Health Service Executive (Ireland) - Clinical Guidelines

56. Diagnosis, staging and treatment of patients with lung cancer

not demonstrated an improvement in overall survival and is not recommended. (B) 2.6.5.3 In patients with stage IV NSCLC who do not experience disease progression after 4-6 cycles of platinum-based double agent chemotherapy, there is insufficient evidence to recommend maintenance therapy with erlotinib. (B) 2.6.6.1 In elderly patients (age 70-79 years) with stage IV NSCLC who have good performance status and limited co-morbidities, treatment with a platinum doublet chemotherapy is recommended. (B) 2.6.6.2 (...) In patients with stage IV NSCLC with a performance status of 2, single agent chemotherapy may be considered. Platinum doublet chemotherapy is suggested over single agent chemotherapy if the performance status of 2 is cancer related rather than co-morbidity associated. (B) 2.6.6.3 Unfit patients of any age (performance status (3-4)) do not benefit from cytotoxic chemotherapy. However if patients harbor an EGFR or ALK mutation positive tumour, they may be considered for treatment with targeted therapies. (C

2017 National Clinical Guidelines (Ireland)

57. A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer (...) to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer The safety and scientific validity of this study is the responsibility

2018 Clinical Trials

58. Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA)

Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA) Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached (...) the maximum number of saved studies (100). Please remove one or more studies before adding more. Study to Compare the Safety of Immediate One-stage IBBR With Expander-Implant Two-stage IBBR Augmented With TiLoop® Bra(COSTA) (IBBR) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read

2018 Clinical Trials

59. Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Capacity to consent to participate in the study as assessed using the Evaluation to Sign Consent tool and investigator judgment Age 25 to 65 years, inclusive, at the time of signing Informed Consent Form Early manifest, Stage I or Stage II HD (defined as TFC of 7-13, inclusive) Genetically confirmed disease (CAG repeat length ≥ 36 in huntingtin gene by direct DNA testing) Body mass index ≥18 and ≤32 kg/m2; total body weight >50 kg Ability (...) Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2018 Clinical Trials

60. One-stage Versus Two-stage Revision of the Infected Knee Arthroplasty

One-stage Versus Two-stage Revision of the Infected Knee Arthroplasty One-stage Versus Two-stage Revision of the Infected Knee Arthroplasty - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. One-stage Versus (...) Two-stage Revision of the Infected Knee Arthroplasty The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03435679 Recruitment Status : Recruiting First Posted : February 16, 2018 Last Update Posted : March 6, 2018 See

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>